Evidence map›Paper›PMID 28487307›Full record

ArticleBMJ case reports2017

Aripiprazole-induced hypersensitivity pneumonitis.

Kulothungan Gunasekaran, Swetha Murthi, Jeffrey Jennings, Nazir Lone

Open access · greenAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Aripiprazole-induced Hepatitis: A Case Report.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Kulothungan GunasekaranHenry Ford Health System, Detroit, USA.
Swetha MurthiInternal Medicine, Sinai Grace Hospital, Detroit, USA.
Jeffrey JenningsDivision of Pulmonary and Critical Care, Henry Ford Health System, Detroit, USA.
Nazir LoneInternal Medicine, Pulmonary and Critical Care, Bassett Healthcare, Cooperstown, USA.
Henry Ford Health System · USBassett Healthcare Network · USSinai Grace Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aripiprazole is an atypical antipsychotic agent commonly used in the management of schizophrenia. Aripiprazole has not been reported to have an association with interstitial lung disease. We describe a case of a 36-year-old woman who began to experience respiratory issues shortly after starting aripiprazole and presented to us 4 years later with progressive exertional shortness of breath. High-resolution CT of the chest showed a bilateral ground glass pattern. Video-assisted thoracoscopy with biopsy revealed alveolar septal thickening and an inflammatory infiltrate composed mainly of lymphocytes, suggestive of chronic hypersensitivity pneumonitis. After discontinuing aripiprazole and initiating prednisolone therapy, the patient's pulmonary symptoms improved. This case highlights that aripiprazole can cause hypersensitivity pneumonitis in susceptible individuals.

Indexed as

AdultAlveolitis, Extrinsic AllergicAntipsychotic AgentsAripiprazoleDiagnosis, DifferentialFemaleHumansLung Diseases, InterstitialSchizophreniaTomography, X-Ray ComputedAntipsychotic AgentsAripiprazoleexposuresinterstitial lung diseasepsychiatry (drugs and medicines)unwanted effects / adverse reactions

Identifiers

PMID28487307
PMCPMC5614109
OpenAlexW2613772980

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.